1,623 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,623 shares of the medical research company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its holdings in Natera by 25.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock worth $528,000 after buying an additional 1,155 shares in the last quarter. Chevy Chase Trust Holdings LLC purchased a new stake in Natera in the 1st quarter worth approximately $14,467,000. Envestnet Portfolio Solutions Inc. raised its position in shares of Natera by 19.2% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 9,047 shares of the medical research company’s stock valued at $827,000 after purchasing an additional 1,457 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in Natera by 28.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 17,586 shares of the medical research company’s stock valued at $1,608,000 after acquiring an additional 3,927 shares during the period. Finally, Lisanti Capital Growth LLC purchased a new position in shares of Natera in the first quarter valued at about $1,189,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. The Goldman Sachs Group boosted their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Canaccord Genuity Group lifted their target price on Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Leerink Partners increased their target price on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird raised their target price on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus target price of $125.69.

Natera Trading Up 2.1 %

Shares of NASDAQ NTRA opened at $126.97 on Thursday. Natera, Inc. has a twelve month low of $40.61 and a twelve month high of $133.54. The business has a fifty day simple moving average of $123.75 and a two-hundred day simple moving average of $113.16. The firm has a market cap of $15.70 billion, a PE ratio of -51.82 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s revenue was up 58.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.97) earnings per share. Analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 4,523 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now owns 191,163 shares of the company’s stock, valued at $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Natera news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $113.82, for a total transaction of $307,314.00. Following the completion of the sale, the insider now owns 299,441 shares of the company’s stock, valued at approximately $34,082,374.62. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 4,523 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the transaction, the chief executive officer now directly owns 191,163 shares in the company, valued at $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,164 shares of company stock worth $6,157,291 over the last quarter. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.